Abstract
For a variety of reasons, most drug candidates cannot eventually pass the drug approval process. Thus, developing reliable methods for predicting clinical trial outcomes of drug candidates is crucial in improving the success rate of drug discovery and development. In this study, we propose an ensemble classifier based on weighted least squares support vector regression (LS-SVR) for predicting successes and failures of clinical trials. The efficacy of the proposed ensemble classifier is demonstrated through an experimental study on PrOCTOR dataset, which consists of informative chemical features of the drugs and target-based features. Comparing random forest and other models, the proposed ensemble classifier obtains the highest value for the area under the receiver operator curve (AUC). The results of this study demonstrate that the proposed ensemble classifier can be used to effectively predict drug approvals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1D1A1B07042349). This work was supported by "Human Resources Program in Energy Technology" of the Korea Institute of Energy Technology Evaluation and Planning (KETEP), granted financial resource from the Ministry of Trade, Industry & Energy, Republic of Korea (No. 20174030201740). This research was supported by the Bio Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2019M3E5D4066897).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all data referred to in the manuscript are not available.